BU-NOT-SET

CONTACT US
Fixed dose combinations - for improved patient compliance
  • Drug product
mini-tablets
Fact sheet
The current state of contract manufacturing
  • Industry trends
Eyes
Insight
The potential impact of Brexit on patient safety
  • Industry trends
Eyes
Insight
EU FMD: After the deadline
  • Manufacturing
Eyes
Insight
The importance of supply chain security
  • Manufacturing
Eyes
Insight
ADC development: setbacks and key developments
  • Drug substance
Lab equipment
Insight
Cytotoxic unsaturated electrophilic compounds commonly target the ubiquitin proteasome system
  • Drug substance
Eyes
Insight
CDMO trends: Drug development and industry consolidation
  • Industry trends
Eyes
Insight
Consolidation in the CDMO Market
  • Industry trends
Eyes
Insight
White paper
  • Biologics
Product Quality in the Advanced Therapies Manufacturing
Insight
  • Biologics
Navigating ATMP fill and finish complexities
Insight
  • Biologics
The power of analytics and AI in the era of continuous RNA manufacturing
Insight
  • Biologics
Reimagining the RNA manufacturing space: An interview with ReciBioPharm’s leaders
Insight
  • Biologics
Unlocking the potential of mRNA: Inside ReciBioPharm's Watertown site
Insight
  • Biologics
Industry 5.0 in action: AI-driven continuous manufacturing for RNA therapeutics
Insight
  • Drug product
  • Manufacturing
Choosing the optimal container format for sterile drug products
Insight
  • Manufacturing
FDA inspection success at Recipharm’s site in Bengaluru, India
Fact sheet
  • Drug product
  • Manufacturing
Lyophilisation Services